CD274 and neoplasm: ALKi have been shown to modulate the immunosuppressive microenvironment of ALK-mutated NSCLC by inducing upregulation of human leukocyte antigen (HLA), tumor-associated antigens and decreasing checkpoint molecule (16, 17, 24) expression, such as PD-L1 (16).